Takaku F
Third Dept. of Internal Medicine, Faculty of Medicine, Univeristy of Tokyo.
Gan To Kagaku Ryoho. 1989 Nov;16(11):3550-3.
Clinical usefulness of G-CSF, GM-CSF and M-CSF was summarized. These CSFs had been demonstrated to accelerate the recovery from neutropenia after anti-cancer chemotherapy and bone marrow transplantation. CSFs were also effective in some patients with aplastic anemia, myelodysplastic syndrome (MDS) and idiopathic neutropenia among children. An increase of neutrophils was observed in these patients responding to CSFs. Few patients with aplastic anemia and MDS, however, responded to G-CSF with an increase of reticulocytes and thrombocytes in addition to neutrophils. Combination of G-CSF with anti-leukemic agents for the treatment of refractory and relapsed acute non-lymphocytic leukemia (ANLL) or as the conditioning for bone marrow transplantation to refractory ANLL patients was found to be quite effective. Possible usage of GM-CSF and M-CSF for cancer treatment by stimulating anti-cancer functions of monocytes-macrophages was also discussed. Furthermore, GM-CSF and M-CSF were demonstrated to decrease serum cholesterol level in rabbits as well as in patients. Possible mechanism of this cholesterol-lowering effect was also discussed.
总结了粒细胞集落刺激因子(G-CSF)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)和巨噬细胞集落刺激因子(M-CSF)的临床应用价值。这些集落刺激因子已被证明可加速抗癌化疗和骨髓移植后中性粒细胞减少症的恢复。集落刺激因子对部分再生障碍性贫血、骨髓增生异常综合征(MDS)患儿及特发性中性粒细胞减少症患者也有效。在对集落刺激因子有反应的这些患者中观察到中性粒细胞增加。然而,很少有再生障碍性贫血和MDS患者除中性粒细胞增加外,对G-CSF有网织红细胞和血小板增加的反应。发现G-CSF与抗白血病药物联合用于治疗难治性和复发性急性非淋巴细胞白血病(ANLL)或作为难治性ANLL患者骨髓移植的预处理相当有效。还讨论了GM-CSF和M-CSF通过刺激单核细胞-巨噬细胞的抗癌功能用于癌症治疗的可能用途。此外,GM-CSF和M-CSF在兔子及患者中均被证明可降低血清胆固醇水平。还讨论了这种降胆固醇作用的可能机制。